AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays
NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.
- NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.
- The application of ultra-sensitive chromatin mapping assays, such as CUT&Tag, to spatial techniques is critical to the study of biological mechanisms in development and disease.
- AtlasXomics has commercialized DBiT-seq for spatial ATAC-seq assays to map chromatin accessibility and is partnering with EpiCypher to introduce spatial CUT&Tag for profiling chromatin proteins, including histone PTMs and transcription factors.
- EpiCypher holds key rights to CUT&Tag technology and a proprietary nucleosome-based approach to develop ultra-efficient antibodies for spatial and single cell CUT&Tag assays.